Title: A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab
Associated condition: Ulcerative Colitis
Status: Currently enrolling
Brief summary: A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
Primary objectives:
Change from Baseline in Bowel Urgency Severity Urgency Numeric Rating Score (UNRS)
Estimated length of study: It is estimated that the study be fully completed by February 28, 2025.
For more detailed information on this research trial, including eligibility and study design, please visit the clinical trial page at U.S. National Library of Medicine’s website. Note you can submit your information for consideration by submitting the contact form on this page.
